Circulating and extracellular microRNAs as new diagnostic biomarkers for gynecological cancers

Česká verzia

Authors: Luděk Záveský ¹; Eva Jandáková ²; Radovan Turyna ³; Lucie Langmeierová ⁴; Vít Weinberger ⁵; Luboš Minář ⁵
Authors place of work: Ústav biologie a lékařské genetiky, 1. LF UK a VFN, Praha, přednosta doc. MUDr. Milada Kohoutová, CSc. ¹; Ústav patologie LF MU a FN Brno, přednosta doc. MUDr. Leoš Křen, Ph. D. ²; Onkogynekologické centrum, Ústav pro péči o matku a dítě, Praha, vedoucí MUDr. Radovan Turyna, Ph. D. ³; Fakultní transfuzní oddělení, VFN, Praha, primářka MUDr. Daniela Dušková ⁴; Onkogynekologické centrum. Gynekologicko-porodnická klinika LF MU a FN Brno, vedoucí as. MUDr. Luboš Minář ⁵
Published in the journal: Prakt Gyn 2014; 18(4): 275-280
Category: Oncogynecology: Original Article

Summary

Small, non-coding molecules of RNA, microRNAs, have been shown to participate in regulation of key biological processes in the cells. They regulate the expression at post-transcriptional level by binding to target mRNA, resulting in mRNA degradation or translation inhibition. The most recent investigations revealed that microRNAs may occur not only in the cells, but also in many body fluids. Differential expression of particular microRNAs is often associated with many pathological states. Therefore, the detection of deregulated microRNAs in diagnostically relevant samples such as blood, plasma/serum, or urine may become the basis for the establishment of novel diagnostic procedures. Finding alternative diagnostic biomarkers for gynecological cancers is the goal of many recent investigations. We present here the survey of novel circulating and extracellular microRNAs which have been found deregulated in ovarian cancer, endometrial cancer and cervical cancer, particularly in blood, plasma/serum and urine samples.

Key words:
diagnosis – cervical cancer – endometrial cancer – ovarian cancer – blood – microRNA – urine – plasma – serum

Zdroje

1. Iorio M, Croce C. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143–159.

2. Weber JA, Baxter DH, Zhang SL et al. The MicroRNA Spectrum in 12 Body Fluids. Clin Chem 2010; 56(11): 1733–1741.

3. Witwer KW, Buzas EI, Bemis LT et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. Journal of Extracellular Vesicles 2013; 2: 20360. Dostupné z DOI: <http://doi: 10.3402/jev.v2i0.20360>.

4. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: The mystery of their origin and function. Trends Biochem Sci 2012; 37(11): 460–465.

5. Hausler SFM, Keller A, Chandran PA et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010; 103(5): 693–700.

6. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110(1): 13–21.

7. Resnick KE, Alder H, Hagan JP et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112(1): 55–59.

8. Zavesky L, Jancarkova N, Kohoutova M. Ovarian cancer: Origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 2011; 58(6): 457–468.

9. Xu YZ, Xi QH, Ge WL et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention 2013; 14(2): 1057–1060.

10. Guo F, Tian J, Lin Y et al. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res 2013; 41(5): 1456–1461.

11. Kan, CWS, Hahn MA, Gard GB et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 2012; 12: 627. Dostupné z DOI: <http://doi: 10.1186/1471–2407–12–627>.

12. Zheng H, Zhang L, Zhao Y et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE 2013; 8(11): e77853. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0077853>.

13. Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gyn Cancer 2013; 23(4): 673–679.

14. Erickson BK, Conner MG, Landen Jr CN. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013; 209(5): 409–414.

15. Suryawanshi S, Vlad AM, Lin HM et al. Plasma MicroRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013; 19(5): 1213–1224.

16. Ji T, Zheng ZG, Wang FM et al. Differential microRNA expression by solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev 2014; 15(4): 1739–1743.

17. Shapira I, Oswald M, Lovecchio J et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 2014; 110(4): 976–983.

18. Torres A, Torres K, Pesci A et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012; 12: 369. Dostupné z DOI: <http://doi: 10.1186/1471–2407–12–369>.

19. 19 Torres A, Torres K, Pesci A et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013; 132(7): 1633–1645.

20. Jia W, Wu Y, Zhang Q et al. Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett 2013; 6(1): 261–267.

21. Záveský L, Jandáková E, Turyna R et al. Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study. [přijato k publikaci/accepted for publication].

22. Yu J, Wang Y, Dong R et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol 2012; 138(4): 671–674.

23. Chen J, Yao D, Li Y et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 2013; 32(3): 557–567.

24. Zhao S, Yao D, Chen J et al. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers 2013; 17(8): 631–636.